COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
BIND Biosciences develops targeted polymeric nanoparticle therapeutics (Accurins) using Medicinal Nanoengineering to concentrate drugs at disease sites; lead candidate BIND-014 is in Phase 1 for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
